NEW YORK, May 26, 2017 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zoompass Holdings, Inc. (“Zoompass” or the “Company”) (OTCMKT: ZPAS). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Zoompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On May 9, 2017 Zoompass disclosed that it had been “made aware of and requested by the OTC Markets Group, Inc. to comment on recent trading and potential promotional activity”. Following this announcement, shares fell $1.67 or over 45% over three trading days. On May 25, 2017, Seeking Alpha issued an article alleging that Zoompass had erroneously denied its involvement with a scheme designed to promote Zoompass’ stock; and that Zoompass had purposely kept hidden the fact that the Company’s CEO was involved in a pump-and-dump scheme.
On this news, shares of Zoompass fell $0.70 or over 23% to close at $2.25 per share on May 25, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zoompass-holdings-inc–zpas-300464785.html
SOURCE Pomerantz LLP
Copyright © 2017 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.